22 May 2017 07:00
PRESS RELEASE
FOR IMMEDIATE RELEASE
Appointment of N+1 Singer as joint broker
London, UK - 22 May 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces the appointment of N+1 Singer as its joint broker with immediate effect. Numis Securities Limited remains nominated advisor and joint broker.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 503205 | |
Miroslav Reljanovic (Chief Executive Officer) | ||
Stephen Stamp (Chief Financial Officer) | ||
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | |
Michael Meade / Freddie Barnfield (Nominated Adviser) | ||
James Black (Joint Broker) | ||
N+1 Singer | Tel: +44 (0) 20 7496 3000 | |
Alex Price (Joint Broker) | ||
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 | |
Chris Gardner / Mary-Jane Elliott / Ivar Milligan | ergomed@consilium-comms.com | |
MC-Services - for Continental European enquiries | Tel: +49 211 5292 5222 | |
Anne Hennecke | ||
About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed acquired a pipeline of proprietary development products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.